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Abstract
The brainstem-based pedunculopontine nucleus (PPN) traditionally associates with motor function, but undergoes extensive
degeneration during Parkinson’s disease (PD), which correlates with axial motor deficits. PPN-deep brain stimulation (DBS) can
alleviate certain symptoms, but its mechanism(s) of action remains unknown.We previously characterized rats hemi-intranigrally
injected with the proteasomal inhibitor lactacystin, as an accurate preclinical model of PD. Here we used a combination of
chemogenetics with positron emission tomography imaging for in vivo interrogation of discrete neural networks in this rat model
of PD. Stimulation of excitatory designer receptors exclusively activated by designer drugs expressed within PPN cholinergic
neurons activated residual nigrostriatal dopaminergic neurons to produce profound motor recovery, which correlated with striatal
dopamine efflux as well as restored dopamine receptor 1- and dopamine receptor 2-based medium spiny neuron activity, as was
ascertained with c-Fos-based immunohistochemistry and stereological cell counts. By revealing that the improved axial-related
motor functions seen in PD patients receiving PPN-DBS may be due to stimulation of remaining PPN cholinergic neurons
interacting with dopaminergic ones in both the substantia nigra pars compacta and the striatum, our data strongly favor the PPN
cholinergic–midbrain dopaminergic connectome as mechanism for PPN-DBS’s therapeutic effects. These findings have impli-
cations for refining PPN-DBS as a promising treatment modality available to PD patients.
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Introduction
Targeting of different brain regions using deep brain stimula-
tion (DBS), as a therapeutic option available to Parkinson’s
disease (PD) patients, has been successfully used as a surgical
approach to treat both the symptoms (e.g., tremor) and also the
side effects of dopamine (DA) replacement strategies (e.g.,
dyskinesias) for more than 2 decades [1]. Low-frequency
DBS can be targeted to the pedunculopontine nucleus
(PPN), leading to an improvement in motor-related symp-
toms, particularly gait and postural abnormalities, which affect
a significant number of PD patients [2–5]. The PPN, located in
the dorso-lateral mesopontine tegmentum, is a highly hetero-
geneous neuronal structure, primarily composing of choliner-
gic, glutamatergic, and gamma-aminobutyric acid
(GABA)ergic neurons [6–13]. Clinical interest in the PPN as
a DBS target stems from the partial denervation of PPN cho-
linergic neurons (where in the intact brain, such neurons in-
nervate the basal ganglia motor loop [9, 14]) observed in
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postmortem brains of PD patients [9, 15, 16]. The eventual
loss of cholinergic innervation not only contributes to the
electrophysiological anomalies that affect the basal ganglia
of PD patients, but also leads to the overactivity of the
PPN’s resident glutamatergic neurons [17], which innervate
dopaminergic (DAergic) neurons of the substantia nigra pars
compacta (SNpc). It has been postulated that this effect could
accelerate the DAergic degeneration seen in PD-affected
brains [18]. Potentially, PPN-DBS could normalize basal gan-
glia electrophysiology and protect the remaining SNpc
DAergic neurons [19, 20]. However, because of the PPN’s
mixed neuronal population, it has, until the recent develop-
ment of improved cell-type–specific modulatory tools, been
impossible to hypothesize which neuronal subtype(s) deliver
the clinical benefits associated with PPN-DBS.
In an earlier study, we utilized selective viral vector-driven
expression of an excitatory Gq-coupled DREADD (designer
receptors exclusively activated by designer drugs) in PPN
cholinergic neurons of a unilateral lactacystin rat model of
PD. In this animal model, selective stimulation of the remain-
ing PPN cholinergic neurons by the DREADD agonist, cloza-
pine N-oxide (CNO), for mimicking selective PPN choliner-
gic DBS, almost completely reversed the motor deficits seen
in this PD model [11, 12]. This study supports the hypothesis
that it is the cholinergic neuronal population, projecting from
the PPN, which delivers some of the clinical benefits associ-
ated with PPN-DBS. Cholinergic axons project from the PPN
to various basal ganglia targets, including the SNpc [21, 22],
the thalamus [23, 24], and the striatum [25]; hence, the ques-
tion remains as to which PPN cholinergic pathway is respon-
sible for the clinical benefits associated with PPN-DBS. PPN
cholinergic neurons projecting to the striatum, synapse with
the nigrostriatal DAergic neurons, with studies in rodents,
have demonstrated that stimulation of PPN cholinergic neu-
rons leads to activation of nigrostriatal DAergic neurons [21,
26]. In the present study, we uniquely combined our PPN
cholinergic DREADD-PD rat model with positron emission
tomography (PET) brain scans, utilizing the DR2/3 ligand
[11C]PHNO, to test our hypothesis that the CNO-induced mo-
tor improvement is due to PPN cholinergic-induced DA re-
lease from nigrostriatal DAergic terminals in the striatum.
Additionally, we utilized the neuronal activity marker c-Fos
to determine whether the CNO-driven motor benefits seen in
this animal model of PD were due to changes in activity of
neural circuits known to facilitate voluntary movement. In
particular, we compared the activity between the prokinetic
“direct” and inhibitory “indirect” pathway projection neurons
that originate from distinct populations of striatal medium
spiny neurons (MSNs) to project to different output structures.
Finally, to ascertain whether PPN cholinergic projections to
the thalamus contribute to the CNO-induced motor recovery
seen in the current PD model, we measured c-Fos expression
within neurons of the SNpc, as well as the ventrolateral (Vl)
and ventromedial (Vm) thalamic subnuclei, with and without
DREADD-based stimulation of PPN cholinergic neurons.
Materials and Methods
Laboratory Animals and Experimental Model
Animal experiments were approved by an ethics panel at
Imperial College London (Ref: BMS39UNNGB2015) and
were performed in accordance with the Animals (Scientific
Procedures) Act, 1986 (UK) for the care and use of experi-
mental animals as well as the European Communities Council
Directive (2010/63/EEC).
We used choline acetyltransferase (ChAT)::Cre transgenic
rats [27], in which Cre-recombinase is exclusively expressed
within cholinergic neurons. Long–Evans hemizygous
ChAT::Cre founder rats, obtained from the Missouri Mutant
Mouse Regional Resource Centre (University of Missouri,
USA) were bred with Long–Evans wild-type (WT) rats
(Charles River Laboratories, Germany), for producing Cre+
offspring. Breeding of ChAT::Cre rats took place at the animal
facility of Imperial College London, where the offspring
underwent genotyping. For this, ear punches were collected
from each rat at weaning age. Genomic DNA was extracted
from each sample to genotype the Cre-recombinase transgene
and therefore distinguish Cre-expressing from non-Cre-
expressing littermate rats. Genotyping was performed by po-
lymerase chain reaction, using the following primer se-
quences: 5″-AGCGATGGATTTCCGTCTCT (forward) and
5″-CACCAGCTTGCATGATCTCC (reverse). A positive
band consisted of approximately 200 base pairs.
To test the present hypothesis, we stimulated PPN cholin-
ergic projection neurons by overexpressing an excitatory
DREADD (hM3Dq) consisting of a modified human M3
muscarinic receptor (hM3) fused to a fluorescent marker
(mCherry) (Fig. 1A), which is selectively activated by the
ligand, CNO [12, 29], but has no biological effect on native
receptors. A Cre-dependent adeno-associated virus, serotype
2 (AAV2), delivered the hM3Dq construct stereotaxically into
the left PPN, to facilitate DREADD expression within PPN
cholinergic neurons of transgenic rats (Fig. 1B). The approach
permitted restricted expression of the DNA encoding hM3Dq
in rats’ cholinergic neuronal population, with spatial restric-
tion to the PPN.
In our previous studies [10–13], we demonstrated that the
unilateral nigral lactacystin model of PD not only produced a
partial lesion of the DAergic nigrostriatal pathway, but also
cholinergic neuronal loss in the PPN, thereby mirroring what
is observed in PD patients, and hence highlighting the suitabil-
ity of this model for the current study. Intracranial injections of
ChAT::Cre rats with hM3Dq DREADD were carried out while
the animal remained anesthetized for the lesion surgery (Fig.
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1A). In total, 44 adult male rats (8-12 weeks old, weighing 300-
400 g) were randomly assigned to 1 of 2 treatment groups:
those receiving a sham (lactacystin vehicle only) lesion of the
SNpc in combination with stereotaxic infusion of the
DREADD-containing AAV2 into the PPN (n = 20) versus par-
kinsonian rats produced through intranigral, unihemispheric
stereotaxic injection of the ubiquitin proteasomal inhibitor
lactacystin [11, 12], combined with an intra-PPN infusion of
the same excitatory DREADD-containing viral vector as used
for the control animals (n = 24).
All rats underwent behavioral assessment at 2 time points:
at baseline, conducted presurgically, when they had attained a
weight of 250 g, whereas assessment was repeated at 5 weeks
after surgery. During the later assessment, behaviors were
conducted twice—in the CNO OFF state (following a
vehicle-only intraperitoneal (i.p.) injection) and CNO ON
state (following a 1-mg/kg i.p. injection of CNO in 0.9% nor-
mal saline with 10% DMSO (dimethyl sulfoxide)). Both le-
sioned (n = 6) and sham-lesioned rats (n = 4) were subjected to
micro-PET imaging, in which the level of endogenous striatal
DA release was quantified in vivo as the displacement of
[11C]PHNO ligand from D2/3Rs. Subsequently, during
CNO-mediated DREADD-based stimulation (CNO ON), the
animals were sacrificed for gamma counter assessment of
[11C]PHNO levels in the brain extracts. Stereological evalua-
tion for validating the DAergic SNpc and cholinergic PPN
lesions was carried out on all animals. Additional animals
(lactacystin-lesioned: n = 6; sham-lesioned: n = 4) that did
not undergo micro-PET scanning represented the baseline,
non-DREADD stimulated (CNO OFF) state for gamma count
measurements. A second group of lesioned (n = 12) and sham-
lesioned rats (n = 12) were sacrificed (followed by transcardial
perfusion to optimally preserve brain tissue for histological
analyses), after they had completed the final behavioral test.
Brain tissues from these animals were used for quantifying
PPN cholinergic c-Fos-immunoreactive (ir), hM3Dq-
mCherry expression, and striatal MSN D1/2R activation
levels. For this set of animals, half the toxin-lesioned (n = 6)
and half the sham-lesioned rats (n = 6) were sacrificed during
CNO ON, whereas the rest of the cohort was sacrificed during
CNO OFF (lactacystin-lesioned, n = 6; sham-lesioned, n = 6).
Drugs
Guettier and others [30] showed that in mice that had received
a single intraperitoneal injection of CNO (1 mg/kg), CNO
plasma levels peaked after 15min and only decreased 2 h after
injections. This study, as well as the study by Alexander and
others [31], reported that CNO remains systemically active in
rodents for up to 10 h after administration. Such published
data on CNO’s duration of action provided us with guidance
as to the appropriate time window in which to carry out the
CNO-induced behavioral and micro-PET assays. CNO (Enzo
Life Sciences, Plymouth Meeting, PA, USA) was dissolved in
DMSO and then diluted in a 0.9% sterile saline solution, to
yield a final DMSO concentration of 10%. The drug solution
was administered intraperitoneally at a dose of 1 mg/kg. CNO
vehicle injections consisted of sterile saline containing 10%
DMSO. D-amphetamine sulfate was purchased from Sigma-
Aldrich and was administered at a dose of 5 mg/kg, dissolved
in 0.9% saline. All drugs were injected intraperitoneally.
Virus Production and Stereotaxic Injections
For generating the activating DREADD hSyn-DIO-hM3Dq-
mCherry (containing the H134R mutation), we followed pro-
tocols reported in our previous work [12]. Briefly, the hM3Dq
coding sequence [31, 32] fused in-frame with the fluorescent
protein (mCherry) at the C terminus and driven by the elon-
gation factor 1 alpha promoter was provided by the laboratory
of Prof. Brian Roth (Viral Vector Core Facility, UNC, Chapel
Hill, USA; Addgene plasmid ID: 44361). Our laboratory
cloned the gene sequence in a Cre-dependent configuration
into an AAV, to incorporate the gene of interest in a double-
inverted open reading frame. Hence, when Cre is absent in a
cell, the fusion construct hM3Dq-mCherry is retained in an
inverse, nonsense orientation, thus limiting DREADD expres-
sion to ChAT-ir neurons in these ChAT::Cre rats. A flip-
excision switch was added to allow stable transgene inversion
[33]. The AAV viral construct was purified through a series of
sucrose and cesium chloride ultracentifugation steps and dial-
ysis, sequence verified, and then packaged in AAV2 serotype
coat proteins by Vector Biolabs (Philadelphia, USA). Final
pellets were suspended in 0.1 M phosphate-buffered saline
(PBS) at a titer of approximately 1.4 × 1013 genomic
copies/ml. Aliquots of virus lots were stored at − 80 °C until
needed for stereotaxic injection.
To selectively express the hM3Dq receptors in cholinergic
(ChAT-ir) neurons in the unilateral (left-sided) PPN of the rats,
we injected the AAV2 vector containing the fused hM3Dq
construct through a 2-mm burr hole drilled over the PPN,
using the coordinates: anterior–posterior (AP) − 7.8 mm and
medio-lateral (ML) + 1.8 mm (relative to bregma) [12]. The
injection was made using a removable 32-gauge needle
(7762-05, Hamilton, Reno, USA), attached to a 10-μl injector
syringe (700 series, Hamilton) and driven by a microinjector
syringe pump (11 Plus, Elite Series, Harvard Apparatus,
Holliston, USA). The construct (1.5 μl, delivered at a constant
rate (0.2 μl/min)) was delivered at a depth of − 7.0 mm (ven-
tral–dural) relative to the dural surface of the brain. The needle
was then lowered further 0.2 mm, to reach a depth of −
7.2 mm, where a further 1.5 μl was delivered, at the same rate
as the first viral delivery. For delivering 1 μl lactacystin solu-
tion (4 μl of 2.5 μg/μl, Enzo Life Sciences, UK) or vehicle
(sterile saline, pH 7.4), a second bore hole was drilled through
the cranium over the SNpc, using coordinates we reported in
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our previous work [10–13]. Sham- and toxin-lesioned groups
were operated on in a randomized manner, during the same
surgical session.
Following the injections, the needle was left in situ for
5 min, before slowly retracting it from the brain. The skin
incision was then closed with 4-0 monofilament nylon suture
(Ethicon, Somerville, USA), with rats then left to recover in a
heated recovery chamber. Fluid replacement (5 ml
glucosaline, containing 0.18% NaCl and 4% glucose; Baxter
Health Science Ltd., UK) was administered intraperitoneally
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after surgery. Rats were assessed daily for weight, general
appearance, and the sutures’ condition for at least 7 days fol-
lowing surgery. At 7 to 10 days after surgery, the sutures were
removed.
Behavioral Testing
All rats (n = 44 in total; lactacystin-lesioned: n = 24; sham-
lesioned: n = 20) utilized in this study, regardless of the exper-
imental arm they were assigned to (to either incorporate
micro-PET imaging or not), were subjected to the full battery
of behavioral tests. All toxin- and sham-lesioned rats were
subjected to behavioral testing before and after CNO-
induced neuronal activation, with data analysis that was per-
formed by an investigator blind to the experimental grouping
of the animal test subjects. The first assessment was per-
formed at baseline (prior to surgery), once rats had reached a
minimumweight of 250 g, whereas the second was performed
at 5 weeks after surgery. For both the first and second testing
sessions, all rats were tested on the same day for the full test
battery, with testing for CNO ON that commenced at 40 min
after administering CNO. Amphetamine-induced rotations
were performed on a single occasion, at 3 weeks after surgery
to confirm lesioning status, by counting the number of clock-
wise and anti-clockwise rotations a rat made over a 15-min
period, commencing 20 min after amphetamine dosing.
Open Field
The rats’ activities when placed in a white plexiglass open
field (OF) arena (90 cm long × 90 cm wide × 60 cm deep)
were recorded (5 min) by a video camera suspended above
the OF. Each animal’s movements were tracked digitally using
ANY-Maze software (Stoelting ANY-Maze, Wood Dale,
USA), supplemented by keystroke inputs of specifically ob-
served behaviors, namely rearing and grooming. A total of 20
parameters were assessed, covering a range of motor func-
tions: total distance traveled (m), average speed (m/s), maxi-
mum speed (m/s), time spent mobile (s), time spent immobile
(s), number of ambulations, duration of ambulations (s), aver-
age number of ambulations, frequency of ambulations, num-
ber of immobile bouts, total number of rotations, total number
of clockwise rotations, total number of anti-clockwise rota-
tions, number of rearing episodes, duration of rearing (s), rear-
ing frequency, number of grooming episodes, duration of
grooming bouts (s), and grooming frequency.
Limb-Use Asymmetry (“Cylinder”) Test
Rats were subjected to the limb-use asymmetry (“cylinder”)
test, for assessing the animals’ use of the ipsilateral (unim-
paired), contralateral (impaired), and both limbs making con-
tact with the inner wall of a transparent plexiglass cylindrical
enclosure (diameter 20 cm; height 40 cm), also referred to as
“wall placement.” Rats were also assessed for the degree of
inner wall exploration undertaken with the forelimbs, termed
“serial-stepping” [11, 12]. Placement of a rat inside the cylin-
der encouraged upright support against the cylinder’s walls
[34, 35], revealing forelimb asymmetries and allowing for
comparing usage by the affected limb to that by the unaffected
limb, because of the unilateral administration of lactacystin
that produced motor asymmetry. For all testing phases (base-
line/CNOOFF and CNOON), 10 rears/rat were video record-
ed. A rat’s movements were scored by means of slow-motion
playback of the recording. Instances were recorded where a rat
Fig. 1 DREADD expression within unilateral rat PPNs. (A) DREADD
incorporation into the host and its subsequent translation depends on Cre-
recombinase, expressed under a ChAT promoter in ChAT::Cre transgenic
rodents. In such animals, only cholinergic neurons possess the cellular
machinery to express DREADD. (B) Stereotaxic injection of DREADD
via an AAV vector into the left PPN (red dot). A second stereotaxic
injection delivered lactacystin to the left SNpc (blue dot), rendering rats
hemiparkinsonian. (C) The DAergic lesion produced amphetamine-
induced ipsiversive rotations; sham controls demonstrated symmetric
net rotations. (D) DAergic lesions were quantified by stereologically
counting ipsilateral versus contralateral SNpc TH-ir neurons. (E)
Stereological counts of the same rats revealed significant (48.5%) loss
of ipsilateral PPN ChAT-ir neurons in lesioned rodents (n = 24) versus
counts made in the contralateral hemisphere. Bilateral PPNs of sham
control rats (n = 20) were left intact. (F) mCherry-tagged hM3Dq
expressed robustly within Cre + PPN cholinergic neurons. The low mag-
nification (×10 air) photomicrographs (top panel) showChAT-mCherry-ir
neurons stained in a representative sham-lesioned rat. The image on the
far left shows the unmagnified version of the merged panel (on the far
right in the same row of images), the latter having been cropped and
zoomed in to accentuate the ChAT-mCherry-ir neurons’ confinement to
the PPN. The mapped diagram delineates the PPN’s characteristic wedge-
like shape, as defined by the nucleus’ resident cholinergic neurons and
indicates the rat PPN’s anatomical location in relation to surrounding
neural structures. The coronal brain section corresponds to Plate #99
(bregma − 7.92 mm) of a stereotaxic atlas of the rat brain [28]. Labeled
areas correspond to the following brain regions: cuneiform nucleus, in-
termediate part (CnFI); cuneiform nucleus, ventral part (CnFV);
microcellular tegmental nucleus (MiTg); precuneiform area (PrCnF); su-
perior cerebellar peduncle (scp); isthmic reticular formation (isRt). Scale
bar = 30 μm. The high magnification (× 40 air) photomicrographs (bot-
tom panel) show the same neurons. The digital overlay shows all
(arrowheads) but 1 (arrow) of the neuronal group being mCherry-ir.
Scale bar = 50 μm. (G) Stereological counts of ChAT-mCherry-ir PPN
neurons were similar between lesioned (72.6 ± 2%, n = 12) and control
rats (74.1 ± 3.1%, n = 12). (H) CNO-induced c-Fos expression (indicating
neuronal activation) within ChAT-mCherry-ir PPN neurons (arrowheads).
The arrow shows a neuron not expressing c-Fos. Scale bar = 50 μm. The
image in (F) (bottom panel) portrays the same ChAT-ir neurons shown in
(H) (bottom panel). (I) Stereological quantification performed on toxin-
lesioned animals of c-Fos expression within ChAT-mCherry-ir PPN neu-
rons located on the hemispheric side ipsilateral to the lesion increased
significantly (****p = 0.002) between CNO ON (n = 6) and CNO OFF
(n = 6). Relatedly, during CNO ON, c-Fos expression levels within
mCherry-ir PPN cholinergic neurons located ipsilateral to the lesioned
hemisphere increased significantly compared with similar neurons on
the contralateral PPN (**p = 0.0012). Histogram error bars depict SEM
throughout
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made sole use of the ipsilateral (to the lesion) or contralateral
forelimb or the simultaneous bilateral use of both forelimbs
for upright support. An asymmetry score was calculated using
the formula: % contralateral forelimb use = (number of con-
tralateral forelimb placements + ½ number of bilateral fore-
limb placements/number of contralateral + ipsilateral + bilat-
eral forelimb placements) × 100 [35].
Postural Instability Test
The postural instability test (PIT) was performed as previously
described [11, 12, 35]. In brief, a rat was held at 45° in a
“wheelbarrow”-like position over a sandpaper-covered sur-
face, with the tip of the rat’s nose being aligned with the 0
line of a ruler. The experimenter restrained 1 forelimb against
the animal’s torso while moving the animal forward over the
planted forelimb until it made a “catch-up” step to regain its
center of gravity. The new position of the tip of the nose was
then recorded. An average of 3 trials per forelimb per testing
session represented each rat’s respective final score.
Vibrissae-Evoked Forelimb Placement Test
We made use of the vibrissae-evoked forelimb placement
(VEFP) test, which assesses sensorimotor integration across
the midline [35]. Briefly, the animal was held by the torso with
its forelimbs hanging freely. The animal was moved slowly to
the edge of the countertop, until the vibrissae of 1 side brushed
against the edge of a countertop. Intact animals typically place
their forelimb rapidly onto the table surface, in response to
ipsilateral vibrissae stimulation. In contrast, rats with unilater-
al lesions present with deficits in placing the limb contralateral
to the lesion. Animals were assessed on 10 trials per side per
test session. In contrast, rats with unilateral lesions would
present with impairments in the placing response of the limb
contralateral to the lesion. Placing asymmetries were present-
ed as the percentage contralateral and ipsilateral forelimb
placements per trial.
Accelerating Rotarod Task
Motor coordination testing was performed on an accelerating
SDI Rotor-Rod System (San Diego Instruments Inc., San
Diego, CA, USA), with the use of an accelerating rather than
constant speed protocol that was shown to minimize interfer-
ence from learned memory [36]. An initial speed of 5
rotations/min (rpm) was systematically increased to 1 rpm/
10 s. Latency to first fall (s) was recorded on 3 occasions, with
an arbitrary upper limit of 500 s. To limit the effect of motor
learning, animals were subject to no more than 3 trials. Trials
were performed at baseline and repeated at 5 weeks after sur-
gery, in the latter case with vehicle-only (CNO OFF), follow-
ed by a CNO intraperitoneal injection (CNO ON).
[11C]PHNO Radiolabeling
PHNO (4-propyl-3,4,4a,5,6,10b-hexahydro-2H-naphtho[1,2-
b][1,4]oxazin-9-ol) is a DA agonist with predictable DR2/3
sensitivity [37, 38]. When radiolabeled with 11C (or tritiated),
it has been shown to have functional use in assessing receptor
availability in both experimental animals and humans [39].
We utilized [11C]PHNO to determine the effect of CNO ad-
ministration on endogenous DR binding in the striata of rats
expressing the hM3Dq DREADD receptor in the PPN. The
radiosynthesis of [11C]PHNO was performed as described
elsewhere [37]. In brief, for the synthesis of radiochemically
pure [11C]PHNO as a sterile, pyrogen-free solution, [11C]-am-
ide was generated by reacting [11C]-propionyl chloride with 9-
hydroxynaphthoxazine. Subsequently, this was reduced by
lithium aluminum hydride and then purified with high-
performance liquid chromatography.
Micro-PET Imaging
hM3Dq-expressing rats (lactacystin-lesioned, n = 6; sham-le-
sioned, n = 4) were anesthetized by isoflurane inhalation,
with respiration, pulse rate, and temperature monitoring (kept
constant at 37 °C via a heating mat and/or heating lamp).
Rats were placed into the bore (12 cm) of an Inveon Micro-
PET scanner (Siemens, Germany). Each rodent was subject-
ed to 2 scans. The first was during CNO OFF (at 40 min
after receiving CNO vehicle (saline containing 10% DMSO,
1 mg/kg i.p.)). Scanned animals were recovered for a mini-
mum of 24 h after the DMSO vehicle scan, before a second
CNO ON (1 mg/kg, i.p.) scan was performed at 40 min after
administering CNO. For administering the radioligand (5.2 ±
0.4 MBq [11C]PHNO), a direct tail vein cannulation (25 G
angiocath) was performed under a topical EMLA® cream
anesthetic. An attenuation correction CT scan was performed
(lasting 12 min in total) prior to a 60-min dynamic PET scan.
The data was histogrammed and decay corrected to the in-
jection time. The images were then reconstructed using 2D
filter back projection. Immediately following completion of
the scan imaging protocol (constituting CNO ON), rats were
sacrificed, and their brains removed. For a direct tissue com-
parison of radioligand uptake in the brain tissue of the
scanned CNO ON group of rats, a CNO OFF group of rats
was included for measuring emitted gamma radiation by
gamma counter measurements. For this, additional hM3Dq-
expressing rats (lactacystin-lesioned: n = 6; sham-lesioned:
CNO OFF n = 4) underwent a radioligand biodistribution
study. Outside of the scanner, these rats were anesthetized,
their physiological functions monitored, given a CNO vehi-
cle injection (i.p.) as described above, and then administered
the radiotracer via direct tail vein injection. The radiotracer
was allowed to distribute in these animals for the same
length of time as was allowed for the scanned animals
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(60 min). Following animal sacrifice, the brains of both
groups of rats that underwent micro-PET imaging (CNO
ON) and the additional nonscanned ones (CNO OFF) were
removed, with cerebellums and striata that were dissected
bilaterally. The remainder of the brains were kept for subse-
quent stereological evaluation of the SNpc and PPN brain
regions.
Micro-PET-Derived Image Analyses
The regions of interest, the striata and cerebellums, were
drawn by an independent observer blinded to the experimental
grouping of the animal test subjects, by using the co-registered
CT-PET images. To generate the in vivo binding potential
(BPND) values, custom Matlab software (MathWorks,
Natick, MA, USA) was used to apply a simplified reference
tissue model (SRTM) using the cerebellum as a tissue refer-
ence region. ΔBPND denotes the change in DAergic receptor
binding (pre-CNO scan − post-CNO scan). For tissue activity
measurements derived from the gamma counter measures,
individual data were decay corrected to the time of injection,
with data that was expressed as standardized uptake values
((SUV) =%injected dose per gram/weight of animal (kg)).
The data was then normalized to cerebellar activity
(representing a minimal DR2/3 binding reference region).
Data are expressed as SUV (ratio to cerebellum) group means
± standard error of the mean (SEM).
Animal Sacrifice and Tissue Processing
After animals subjected to either PET imaging or cut-and-
count analyses were humanely sacrificed, decapitated, and
their brains extracted, the cerebellums and striata were dissect-
ed out, with the remaining tissue (containing the SNpc and
PPN) that was either snap-frozen in dry ice prechilled
isopentane or postfixed in 4% paraformaldehyde (PFA) prior
to immunostaining. After fixing in 4% PFA for 24 h, the tissue
was placed in 30% sucrose solution for cryoprotection.
Cryoprotected brains were stored at − 80 °C prior to section-
ing. For analyzing the brains of rats that had not received a
PETscan/cut-and-count evaluation, the rats were sacrificed by
sodium pentobarbital overdose and transcardially perfused
with 50 ml heparinized PBS (37 °C), followed by 4% PFA.
The extracted whole brain was kept in 4% PFA for 8 to 12 h,
then cryoprotected using a 30% sucrose solution before freez-
ing for storage at − 80 °C. The brains containing the regions of
interest (ROIs), namely the striatum, SNpc, PPN, and Vl and
Vm thalamus, were coronally sectioned (30 μm) with a cryo-
stat (Bright Instruments, UK) with sections mounted serially
(from most rostral to most caudal) onto glass slides (VWR
International, UK).
Immunohistochemistry and Immunofluorescence
Immunohistochemistry (IHC) staining of the coronal brain
tissue sections containing the PPN was performed to detect
the rate-limiting enzyme ChAT, needed for acetylcholine
(ACh) synthesis. After removing the sections from the −
80 °C freezer, they were left at room temperature (RT) to
dry. Sections were then circled with a hydrophobic slide
marker pen (PAP Pen, Zymed, San Francisco, CA), before
hydrating through a graded series of ethanol (EtOH, Sigma)
and then placing under running tap water for 5 to 10 min.
The sections were incubated for 30 min in 0.3% H2O2
(Sigma) made in 0.05 M Tris buffered saline (TBS) before
applying the primary antibody solution (1:300, polyclonal
goat, AB144P, Millipore, MA, USA) overnight at RT. The
next morning, excess primary antibody was washed off (3 ×
3 min) with 1% PBS followed by incubation in 20% horse
serum (Vector Laboratories, UK) for 1 h, before applying the
biotinylated secondary antibody (1:100, horse anti-goat, BA-
9500, Vector Laboratories) to the sections for 2 h at RT.
Again, excess secondary antibody was washed off with
PBS before a third-layer avidin–biotin–peroxidase complex
(ABC Elite, Vector Laboratories) was applied to the sections
for 1 h at RT. Visualization was performed using 3,3′-diami-
nobenzidine (Vector Laboratories) with cresyl fast violet
counterstaining applied for 3 to 5 min. Sections were
dehydrated in graded EtOH, cleared with xylene, and finally
mounted using DPX (Sigma). The slides were left to dry
completely before microscopic analysis. For IHC staining
of tyrosine hydroxylase (TH)-ir neurons in SNpc-containing
coronal rat brain sections, a similar procedure was followed
using an anti-TH primary antibody (1:300, polyclonal rabbit,
P40101-0, Pel-freeze, AR, USA). After blocking for nonspe-
cific binding with 20% horse serum, horse anti-rabbit bio-
tinylated secondary antibody was applied (1:100, Vector
Laboratories) for 1 h at RT.
Because the transcription factor c-Fos serves as an indirect
marker of neuronal activity, which upregulates in response to
increased neuronal activity [40], we used a c-Fos confocal
immunoassay to quantify the degree of cholinergic PPN neu-
rons resulting from CNO-DREADD excitation. c-Fos immu-
nostaining was performed as described previously [12], using
a sheep polyclonal primary antibody (1:500, AB1584, Merck
Millipore). Animals were deeply anesthetized with sodium
pentobarbital (50 mg/kg) 40 min after administering CNO
(i.p.) and then transcardially perfused, and the brains were
removed, postfixed, and then cryoprotected, as described
above. Similarly, dual immunofluorescent staining of thalamic
neurons comprised of an anti-NeuN primary antibody (1:700,
rabbit polyclonal, ABN78, Merck Millipore) with an anti-c-
Fos one (detailed above), fluorescently tagged with Alexa-
Fluor® 488 and 546 secondary antibodies (both at 1:200,
Thermo Fisher Scientific), respectively.
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To determine the level of hM3Dq-mCherry expression
within PPN cholinergic neurons, on the hemispheric side ip-
silateral to the DREADD delivery site, sequential slides con-
taining the sectioned PPN were identified by gross anatomical
comparison against a stereotaxic atlas [28]. Every sixth sec-
tion was stained with an anti-ChATantibody and fluorescently
tagged with a secondary antibody excitable at 488 nm, as
described above. The DREADD construct carries an
mCherry tag which excites maximally at 587 nm.
Because the activity of DR1-bearing neurons could not be
assessed from the results of the [11C]PHNO binding assay, as
this radioactive agonist rather has DR2/3 selectivity [38], tri-
ple fluorescent staining was performed on striatum-containing
brain tissue sections to determine relative levels of striatal
MSN activation, mediated by PPN cholinergic neuronal acti-
vation. The sequential sections containing striatal tissue were
identified by gross anatomical comparison with a stereotaxic
atlas [28]. The sections were stained with c-Fos (detailed
above) to quantify neural activity in DR1 (1:300, sc-33660,
monoclonal mouse, Santa Cruz, every 6th section) and DR2-
bearing (1:300, sc-5303, monoclonal mouse, Santa Cruz)
striatal MSNs (also using every 6th section in the series),
comparing sections from rats taken before and during PPN
cholinergic stimulation. Simultaneously, sections were stained
with an antibody raised against DARPP-32 (1:300, sc-11365,
polyclonal rabbit, Santa Cruz), to identify striatal MSNs. The
blocking solution consisted of 20% donkey serum, applied to
sections for 1 h at RT. Antibody-binding sites were then visu-
alized using Alexa-Fluor® 546 (donkey anti-sheep) for tag-
ging c-Fos, Alexa-Fluor® 488 (donkey anti-mouse) for iden-
tifying DR1 and DR2, and/or Alexa-Fluor® 405 (donkey anti-
rabbit) for DARPP-32. All secondary antibodies were pur-
chased from Thermo Fisher Scientific and each was applied
at a dilution of 1:200. All antibodies and sera were diluted in
TBS containing 0.1% Triton X-100 (Sigma).
For optimizing the immunofluorescence staining protocols
applied here, we consulted published protocols that utilized
the same primary antibodies applied to rodent brain tissue
sections. This included for detecting DR1 and DR2 [41–43].
For testing each primary antibody staining assay, a “procedur-
al control” stain was included, in which the primary antibody
was omitted, but otherwise the same procedure was used,
including incubating the samples with the relevant secondary
antibody. In these brain tissue sections, no immunolabeling
was observed, to affirm that the secondary antibody did not
in any of the reactions bind nonspecifically to certain cellular
components. In addition, we consulted published guidelines to
determine alternative brain regions known to express the var-
ious target antigens, to thereby comprise positive tissue con-
trol reactions, which were included in the optimization and
quality control steps. For example, for immunolabeling DR1
and DR2, we concomitantly stained brain tissue sections con-
taining the medial frontal cortex, as per previously reported
experiments [44]. On each occasion, such positive control
specimens emitted intense fluorescence signaling.
Stereological Neuronal Counts
Stereological cell count estimations were performed using the
optical fractionator technique [45]. Stained brain sections con-
taining the ROIs (SNpc and PPN) were digitally scanned with
a Nikon Eclipse E800 microscope, equipped with a 3CCD
camera (JVC Ltd., London, UK) under a low magnification
objective lens (× 2.5 air-immersion). On the scanned tiled im-
ages, the ROIs were manually delineated using Image-Pro
Plus image analysis processing software (v. 9.1, Media
Cybernetics, Inc., Bethesda, MD, USA), guided by anatomi-
cal landmarks [28]. Counting frames (SNpc 160 × 140 μm,
PPN 150 × 150 μm) were generated within the respective
ROI, with neurons of interest that were counted via manual
input at × 10 (air) magnification by a single investigator
blinded to the animal treatment. The height sampling fraction
(hsf) was calculated as the height of the optical dissector,
measured by using a Heidenhain microcator (Hedenhain,
Germany), relative to the actual section thickness (30 μm).
The section sampling fraction (ssf) was set at 1/6, because
every 6th section was included in the analysis. Total cell esti-
mates were then obtained by using the formula: N = n-
(1/ssf)(1/asf)(1/hsf), where n equals the number of positive
cells counted and the area sampling fraction (asf) represents
the total area of the counting frame, relative to the ROI area, as
previously described [45].
The degree to which PPN cholinergic neurons contained
hM3Dq-mCherry expression was quantified by performing 2-
channel fluorescent scanning using a Nikon Eclipse E8 micro-
scope with motorized stage (Nikon Instruments, UK). Image
tiling was performed using Surveyor software, to create 2-
channel overlays. Separate counts were made for ChAT-ir
and ChAT-ir/mCherry-ir co-expressing neurons. Sequential
sections containing the SNpc and PPN were separately
immunofluorescently (double)-stained with either c-Fos-TH
or c-Fos-ChAT. c-Fos expression was quantified in SNpc
DAergic neurons and PPN cholinergic neurons using stereol-
ogy, for rats sacrificed during CNO ON versus CNO OFF
state, and in both cerebral hemispheres. Triple-stained c-Fos-
DR1-DARPP-32/c-Fos-DR2-DARPP-32 sections were tiled
and quantified using the same method and stereological pa-
rameters as for PPN lesion quantification, generating instead
counts for DR1- and DR2-bearingMSNs that expressed c-Fos
versus those not expressing c-Fos on both lesioned versus
unlesioned striatal sides and in CNO-DREADD stimulated
versus nonstimulated rodents.
Similarly, for the thalamic neuronal counts, every 6th sec-
tion was selected for staining, with slide scanning of stained
slides and stereological quantification which occurred as de-
scribed for the PPN lesion studies. Neuronal count estimations
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were generated for rats during CNO OFF and CNO ON and
on lesioned versus nonlesioned cerebral sides. Thalamic sub-
divisions were identified based on stereological atlas anatomy
[28], enabling cell counts to be generated for different thalam-
ic subdivisions.
Statistical Analyses
An online calculator (http://powerandsamplesize.com) was
used for estimating statistical power and effective sample
sizes. For computing such values, type I errors were
controlled for by setting the significance level at 5%.
Furthermore, a 2-tailed direction of effect was applied, which
is standard in animal research [46]. For determining the sam-
ple size, a 2-sample Student’s t test was used for comparing
the means obtained by sham control rats to lesioned animals.
Data is presented as mean ± SEM throughout. The α level
was set at 0.05 for all analyses and performed using GraphPad
Prism 7.0 (GraphPad Software, La Jolla, CA, USA). p values
were designated as fol lows: ****p < 0.0001 and
***p < 0.001, extremely significant; **p ≤ 0.01, highly signif-
icant; *p ≤ 0.05, significant; and p > 0.05, n.s. All data points
were examined on scatterplots to evaluate normality. For mul-
tiple comparisons, 1- or 2-way ANOVA tests were employed
as appropriate, with Bonferroni post hoc corrections. For com-
paring the effects in the sham versus lesioned animals, a
Student’s t test was used, whereas a Mann–Whitney test was
used to specifically compare the effects of DREADD-based
stimulation on SUV values in striatal tissue (normalized to the
cerebellum) between the lesioned and nonlesioned animals.
Results
Stereological Cell Counts Confirm
Lactacystin-Induced Nigral Dopaminergic and PPN
Cholinergic Lesions
To validate the ability of an intranigral lactacystin infusion to
produce a rat lesion model that mimics human PD neuropa-
thology, a series of behavioral and IHC-based investigations
were conducted. Amphetamine-induced contralateral rota-
tions made by the rats were counted at 3 weeks after surgery,
as an index of the lesion deficit [47]. Lesioning was consid-
ered successful if rotational behavior demonstrated at least 7
anti-clockwise (a.k.a. ipsiversive) rotations per minute, a
threshold also used in our previously published work [11,
12]. Scores were significantly higher for the lesioned group,
whereas the sham controls demonstrated essentially symmet-
ric net rotations (****p < 0.0001) (Fig. 1C).
Nigral DAergic neuronal counts were quantified using ste-
reology for each sham (n = 24) and lesioned animal (n = 24),
in both the injected (left/ipsilateral) and nonlesioned (right/
contralateral) cerebral hemispheres. At 5 weeks after surgery,
lactacystin lesioning produced a significant 53.9% reduction
in DAergic neuronal density on the lesioned side, producing a
total neuronal count of 5565 ± 398 (mean ± SEM), compared
with the nonlesioned side (12,075 ± 303) (****p < 0.0001)
(Fig. 1D), assessed as TH-ir, the rate-limiting enzyme in DA
synthesis. SNpcDAergic neuronal counts for control rats were
similar between the sham-lesioned ipsi- (11,910 ± 511) and
nonlesioned contralateral sides (11,762 ± 530) (p > 0.05, not
significant (n.s.)) (Fig. 1D). Lesioned animals showed a
48.5% loss of ipsilateral PPN cholinergic neurons (1762 ±
400) compared with the contralateral PPN ones (2934 ± 302)
(****p < 0.0001) (Fig. 1E), a significant reduction also com-
pared with ipsilateral PPN cholinergic neurons of sham-
lesioned controls (3052 ± 444) (****p < 0.0001) (Fig. 1E).
Brain material was derived from rats that had either been
transcardially perfused (lactacystin-lesioned: CNO ON n = 6,
CNO OFF n = 6; sham-lesioned: CNO ON n = 6, CNO OFF
n = 6) or where the brain tissue had been cryopreserved
(lactacystin-lesioned: CNO ON n = 6, CNO OFF n = 6;
sham-lesioned: CNO ON n = 6, CNO OFF n = 6), as the brain
tissue was also required for measuring tissue-associated gam-
ma radiation. Negligible-only measurement differences were
seen between these 2 groups of rats that differed as to the
method by which the brains were collected and preserved
for postmortem analysis, for either SNpc DAergic or PPN
cholinergic neuronal counts. This provided assurance to allow
us to pool data for all lesioned and all sham control rats for this
analysis.
Viral-Mediated hM3Dq Expression
In lactacystin-lesioned rats, stereological counts made of PPN
(lesioned hemisphere) cholinergic neurons (identified by fluo-
rescent (green) tagging of ChAT demonstrated robust expres-
sion of hM3Dq-mCherry (Fig. 1F), with a 72.6 ± 2% of all
PPN cholinergic neurons that showed overlap (Fig. 1G).
This was similar between both hemispheres of the sham con-
trols, which showed a 74.1 ± 3.1% overlap (Fig. 1G). In all
cases, representing both lesioned and sham control animals,
no hM3Dq-mCherry expression, in the absence of ChAT co-
expression, was observed in any of the stained sections. Taken
together, these results indicate that our use of Cre-dependent
viral vectors, to permit restricted expression of hM3Dq in
neurons defined by the expression of the cholinergic genetic
marker ChAT, is an effective strategy for targeting the PPN
cholinergic neurons of rats, in order to enable cell-type-
specific manipulations.
The ability of CNO as a muscarinic DREADD ligand, to
activate cholinergic PPN neurons expressing hM3Dq, was
verified by stereologically quantifying immunofluorescence
of the immediate early-gene c-Fos, its expression correlating
with neuronal activation in a well-described cellular pathway
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[48]. We co-analyzed the expression of c-Fos (blue) with
neurons expressing the DREADD-mCherry fusion protein,
to identify virally infected neurons in this brain region (Fig.
1H). The use of a Cre-dependent fluorescence reporter rat
line allowed for restricting DREADD expression to cholin-
ergic neurons, with stereotaxic microinjection of the virus
allowing for spatial specificity of DREADD expression to
the PPN. The number of mCherry-ir cholinergic neurons of
the PPN that co-stained for c-Fos was stereologically quan-
tified for both ipsilateral and contralateral hemispheres in the
postmortem brains of lactacystin-lesioned rodents, by com-
paring the PPNs of CNO-unstimulated (CNO OFF, n = 6)
with CNO-stimulated (CNO ON, n = 6) rats (Fig. 1H).
During CNO OFF, the mean ipsilateral c-Fos expression in
DREADD-transfected PPN neurons of lesioned animals was
50.4 ± 4.1% compared with 54.3 ± 3.4% contralaterally, giv-
ing a negligible interhemispheric difference of 3.9%. In con-
trast, during CNO-DREADD stimulation, this interhemi-
spheric difference increased to 12.6 ± 1.3% because of dis-
proportionate high ipsilateral c-Fos expression levels of PPN
cholinergic neurons (78.4 ± 6.8%), compared with similar
neurons on the contra la tera l s ide (54.3 ± 5.2%)
(**p = 0.0012). Viewed alternatively, stereological counts
made of c-Fos-expressing ChAT-mCherry-ir PPN neurons
located ipsilaterally to the lesioned hemisphere increased sig-
nificantly (****p = 0.002) from CNO OFF to CNO ON
(Fig. 1I). Taken together, these results demonstrate robust
DREADD expression within ipsilateral PPN cholinergic neu-
rons, with stimulation via hM3Dq-CNO that resulted in sig-
nificantly increased levels of cytoplasmic c-Fos protein,
reflecting our previous findings [12].
Stimulation of PPN Cholinergic Neurons
in Parkinsonian Rats Reverses Motor Deficits
We previously showed that stimulation of DREADD-bearing
cholinergic neurons of the PPN alleviates motor deficits
across a number of domains. These findings were verified in
the present study [12]. In the current study, we observed
marked restoration of gait stability, locomotor asymmetry
(measured via the vertical “cylinder” test), and sensorimotor
integration across the cerebral hemispheric midline (assessed
via the VEFP test) (Fig. 2), mirroring the putative effects of
human PPN-DBS. The rats’ performance during accelerating
rotarod testing provided an additional measure of postural
instability beyond the parameters measured in our previous
work [11, 12]. For this, latency to first fall markedly increased
in the lactacystin-lesioned group when testing occurred during
CNO ON (53 ± 28 s) compared with the CNO OFF phase of
testing (33.5 ± 16.5 s) (**p = 0.002) (Fig. 2A). Sham-lesioned
control rats showed consistent performance in this motor-
related parameter, regardless of whether PPN cholinergic neu-
rons were stimulated (p > 0.05, n.s.) (Fig. 2A).
The lesioned rats’mean stepping distances, as was assessed
in the PIT (Fig. 2B), were significantly impaired compared
with control rats during CNO OFF (***p < 0.001). With
DREADD-based stimulation, however, lesioned animals
demonstrated near-perfect recovery in this parameter (***p
< 0.001).
The rats also underwent the limb-use asymmetry “cylin-
der” test (Fig. 2C–F) measuring the rat equivalent of akinesia,
tremor, postural deficits, and dyskinesia, which manifests
when a rat has been placed inside a vertical cylinder and ex-
plores the inside by rearing and touching the walls of the
cylinder, with its forelimb paws providing postural support
[49]. Testing of lesioned rats during CNO OFF produced a
significant performance reduction in several parameters, with
subsequent recovery seen during CNOON, including in “wall
placement” (**p = 0.007) (Fig. 2C) and “wall exploration”
(*p < 0.05) (Fig. 2D), but not for “push off” (p > 0.05, n.s.
(data not shown)) nor landing (p > 0.05, n.s. (data not
shown)). Control rats showed an overall consistent perfor-
mance, with no significant changes seen between baseline
measures and when assessment was repeated at 5 weeks after
surgery.
Responses in the VEFP test (Fig. 2E) were significantly
impaired in lesioned rats, but robustly present at baseline
and in sham control rats. The response was almost entirely
mute in lesioned rats during CNO OFF, but recovered near-
perfectly during CNO ON, reaching near-baseline values
(****p < 0.0001).
Finally, lesioned rats’ number of ambulatory bouts over
10 min in the OF (Fig. 2F) arena increased significantly
d u r i n g CNO ON c om p a r e d w i t h CNO OFF
(***p < 0.001) as opposed to assessment that occurred at
CNO OFF, in which compared with sham control rats, le-
sioned animals were significantly impaired in this measure
(*p = 0.03). In addition, whereas lesioned rats covered
significantly less distance in the OF arena than sham-
lesioned rats over the testing period when CNO OFF test-
ing was performed (***p = 0.0003), lesioned animals re-
covered in this parameter to a significant extent when this
cohort’s performance at CNO ON was compared with CNO
OFF (*p = 0.02) (Fig. 2G). All the other parameters
remained unaffected (p > 0.05, n.s. (data not shown)).
Sham-lesioned rats’ performance across all motor parame-
ters assessed in the OF arena remained consistent, regard-
less of whether the CNO OFF or CNO ON stage was
assessed. The lesioned rats’ performance in the locomotor
parameter “number of ambulations” seems to have im-
proved upon being administered CNO significantly more
than any of the motor-related aspects assessed in our study,
thereby deserving further attention in future work, particu-
larly to better understand the mechanisms behind the seem-
ingly large influence PPN cholinergic–driven stimulation
exerts on this index of motor function. It seems unlikely
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this result reflects a tendency for PPN cholinergic stimula-
tion to induce general hyperactivity in rats, as other
indicators of locomotion in this test were not similarly af-
fected by the same therapeutic intervention. It is known
Fig. 2 SNpc hemi-lesioning produced motor deficits across several do-
mains, which recovered via DREADD-CNO stimulation of remaining
PPN cholinergic neurons. (A) During accelerating rotarod testing of the
lesioned rats, latency to first fall increased from 33.5 ± 16.5 s (CNOOFF)
to 53 ± 28.2 s (CNO ON) (**p = 0.002). Sham-lesioned rodents
displayed consistent, nonimpaired performance regardless of CNO-
induced stimulation or not. (B) At CNO OFF, evaluation during the PIT
revealed reduced average stepping distance because of PPN cholinergic
and SNpc DAergic lesioning compared with sham control rats (***p
< 0.001). Lesioned rats showed significant functional recovery during
CNO ON (***p < 0.001). (C, D) The results of vertical cylinder “wall
placement” and “wall exploration,” respectively. SNpc and PPN hemi-
lesioning produced significant under-use of the contralateral forelimbs,
with subsequent amelioration in performance during CNO ON. (C)
**p = 0.007; (D) *p < 0.05). (E) For lesioned rats, dramatic loss of func-
tion at CNO OFF followed by recovery at CNO ON was particularly
evident in the VEFP test, in which responses to vibrissae stimulation were
terminated in all lesioned animals, but mean response rate recovered near-
completely during CNO ON (****p < 0.0001). (F) In the OF arena,
lesioned rats tended to freeze and/or display reduced motion, but recov-
ered in this aspect during CNO ON (***p < 0.001). (G) For the same
testing paradigm, the lesioned rats covered significantly less distance over
the 10-min test period at CNO OFF compared with CNOON (*p = 0.02)
and also compared with sham control rats at CNO OFF (***p = 0.0003).
Error bars depict SEM throughout. Lactacystin-lesioned: CNO ON n =
12, CNOOFF n = 12; sham-lesioned: CNOON n = 10, CNOOFF n = 10
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that OF arena size can significantly affect ambulations in
rats and mice [50–52]. Future studies to determine whether
the degree of behavioral rescue by DREADD-CNO could
be altered by changing the dimensions of the OF arena will
be insightful.
[11C]PHNO PET and a Reduction of [11C]PHNO Binding
Indicates Striatal DA Release in Consequence
to DREADD-Based Stimulation of PPN Cholinergic
Neurons
PET/CT imaging utilizing the DAergic agonist tracer
[11C]PHNO allowed for noninvasive investigation of the
functional effects of PPN-targeting cholinergic-specific
stimulation on the nigrostriatal DAergic pathway in a
well-validated rat model of PD. Four sham control and 6
lesioned animals underwent a scan at baseline (CNO OFF),
followed by a second scan for CNO ON imaging. A mini-
mum of 24 h was permitted between scans to allow for
radiotracer washout and recovery from anesthesia. The
[11C]PHNO BPND was then estimated by fitting a SRTM
to the time–activity curves (TACs) that had been generated
for the striata and cerebellums. The cerebellum served as a
reference region, replacing a plasma input function to cor-
rect for intersubject differences in the pharmacokinetic de-
livery of the tracer to the brain tissue (Fig. 3A). For the
hemi-lesioned rats, [11C]PHNO BPND during CNO OFF
was consistently higher for the ipsilesioned striata (3.8 ±
0.3) compared with the intact striata (2.8 ± 0.3) (*p < 0.05).
This effect may be due to a combination of factors, includ-
ing a loss of endogenous DA release which would normally
displace [11C]PHNO, or be due to reduced striatal DA
levels, which will in itself trigger a compensatory increase
in DR2-like expression, making target neurons more sensi-
tive to the lower levels of DA.
In the ipsilesional striata of the parkinsonian rats, CNO-
induced stimulation significantly reduced [11C]PHNO binding
(Δchange% 26 ± 5.8) (**p < 0.01) (Fig. 3B) compared with
the CNO OFF phase, which is consistent with an increase in
DA concentration. In the same animals, CNO ON produced a
reduction in [11C]PHNO binding in the contralesional striata
(Δchange% 14 ± 6.2) (*p < 0.05) (Fig. 3C), but to a signifi-
cantly lesser extent than was seen in the ipsilesional striata
(Fig. 3B). In sham control rats, the BPND values taken at
baseline (CNO OFF) showed no significant differences be-
tween the left striata (ipsilateral to the sham-injected SNpc)
(2 ± 0.4) and right striata (on the intact hemispheric side)
(1.99 ± 0.3) striata. CNO-induced stimulation did not signifi-
cantly change the interhemispheric striatal BPND of sham con-
trol rats when compared with this cohort’s CNO OFF values
(Δchange% − 6.09 ± 5.3, n.s.) (Fig. 3B, C).
>To support the in vivo imaging findings, the levels of
radioactivity associated with ex vivo tissue was evaluated
by gamma counting. For this, striata lying ipsilateral and
contralateral to the intranigral stereotaxic injection site and
the cerebellums were excised and then weighed before the
associated radioactivity was measured. SUVs were calcu-
lated and normalized to the reference region (the cerebel-
lum), for which counts were determined. Injected radioac-
tivity dose was measured and decay corrected, as detailed in
the “Materials and Methods” section. Normalized SUVs
were expressed as left:right ratios (L:R striatal SUV) to
enable inter-rat comparisons because of the potential spread
of DREADD in the brain tissue and to control for
intersubject differences in physiology and neurochemistry.
At CNO OFF, the mean [11C]PHNO L:R striatal SUVs of
hemi-lesioned rats was 2.2 ± 0.34, producing a significant dif-
ference compared with the mean L:R striatal SUV ratio of
sham controls (0.81 ± 0.05) (*p = 0.02) (Fig. 3D). This im-
plies greater binding of the radiotracer on the lesioned side,
consistent with lower endogenous DA concentration, which
could be considered a compensatory increase in DR2 expres-
sion. CNO-induced activation produced a significant decrease
(*p = 0.017) in the L:R SUV (1.39 ± 0.10) of the lesioned rats
compared with this group’s CNO OFF values (2.38 ± 0.36); a
similar significant decrease was not observed in sham-
lesioned rats (1.2 ± 0.09, p > 0.05, n.s.) (Fig. 3D). For the
hemi-lesioned rats, baseline [11C]PHNO BPND was consis-
tently higher for the ipsilesional striata compared with the
contralesional striata, consistent with lower endogenous DA
concentration, a compensatory increase in DR2-like expres-
sion, or a combination of both. Taken together, these results
suggest strongly that DREADD-CNO for activating
cholinergic-only neurons projecting from the PPN induced
striatal DA release on the lesioned hemispheric side of
lactacystin-lesioned rats.
PPN Cholinergic Stimulation Induces Upregulated
Neuronal Activity of SNpc DAergic Neurons
The number of bilateral SNpc DAergic neurons expressing c-
Fos (Fig. 4A) was evaluated stereologically in brains collected
from the culled toxin-lesioned rats. Analysis of the lesioned
rats revealed that at CNO OFF, the difference in c-Fos expres-
sion between ipsilateral and contralateral hemispheres was
negligible (p > 0.05, n.s.) (Fig. 4B). However, during CNO-
induced stimulation of the PPN cholinergic neurons, the inter-
hemispheric difference increased by 15.8% (*p = 0.04) (Fig.
4B). This change was due to a disproportionately high level of
SNpc DAergic neurons expressing c-Fos ipsilaterally (79.8 ±
5.5%) during the activated state, compared with the same
hemispheric side but prior to CNO administration (59.9 ±
10.6%) (****p < 0.0001) (Fig. 4B). These findings indicate
that in this rat model of PD, DREADD-induced activation of
cholinergic neurons at the level of the PPN associates with a
substantial increase in SNpc DAergic neuronal activity. This
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also implicates that the cholinergic–DAergic connectome un-
derlies the clinical effectiveness of PPN-DBS, with the natural
downstream target of this neural interaction system being the
striatal DAergic neurons that project from the SNpc.
Fig. 3 PET and BPND analysis indicate striatal DA release upon
DREADD-based stimulation of PPN cholinergic neurons. (A)
Representative PET/CT images at the level of the striatum, pre- (left)
and post-CNO (right) in a representative lesioned (top row images) and
sham-lesioned control rat (bottom row images). The toxin/sham-lesioned
area is indicated by the white arrowhead. For each panel, the TACs of the
right (contralesional) and left (ipsilesional) striata are reported, along with
the SRTM BPND estimates obtained using the cerebellum as reference
region. During CNO OFF, higher [11C]PHNO BPND values were found
within left (ipsilesioned) striata compared with right (contralesioned) stri-
ata; receptor occupancy estimates were comparable at CNO ON. (B)
BPND estimates in the ipsilesional and (C) contralesional striata for
lesioned rats at CNO OFF (n = 6) and CNO ON (n = 6), as well as sham
control rats (CNO OFF: n = 4; CNO ON: n = 4). In hemi-lesioned rats,
BPND estimates were reduced in both the ipsilesional and contralesional
sides during CNO ON compared with baseline; the reduction was partic-
ularly striking on the lesioned hemispheric side. No notable change in
BPND estimates was seen between CNOOFF andCNOON for sham rats.
(D) Left-to-right [11C]PHNO striatal SUV ratios (normalized to the cere-
bellum) were significantly higher pre-CNO in lesioned versus sham rats
(*p = 0.02). In lesioned rats, at CNOON, there was a significant decrease
in the L:R striatal SUV ratio compared with CNO OFF (*p = 0.017).
Error bars depict SEM throughout
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Fig. 4 Activity effects of PPN cholinergic stimulation on striatal SNpc and
thalamic neurons. (A) High-power photomicrographs of nigral TH-c-Fos
co-stained neurons, indicating TH-c-Fos-ir neurons (white arrowheads),
interspersed with c-Fos immunonegative TH-ir neurons (blue arrowheads)
and a single non-DAergic c-Fos-ir neuron (arrow). Scale bar = 20 μm. (B)
The lesioned hemispheric side (vs intact side) of parkinsonian rats displayed
an overall reduction in the number of SNpc nigral TH-ir neurons expressing
c-Fos. The mean c-Fos expression level of remaining SNpc TH-ir neurons
on the ipsilateral (lesioned) side increased significantly (****p < 0.0001)
from the CNO OFF (59.9 ± 10.6%, n = 6) to CNO ON state (79.8 ± 5.5%,
n = 6). Also, during PPN cholinergic stimulation, SNpc DAergic neuronal
activity increased substantially, revealed by an interhemispheric difference
of 15.8% (*p= 0.04). (C) Single-channel and merged photomicrographs
showing DARPP-32, DR1, and c-Fos-ir neurons, respectively. PPN cholin-
ergic neuronal stimulation in lesioned compared with control rats increased
the activity of striatal DR1-bearing MSNs. Scale bar = 50 μm. (D) Single-
channel photomicrographs of DARPP-32, DR2, and c-Fos-ir neurons and 2
two-channel overlays showing DR2-MSNs and c-Fos-DR2 expressing
MSNs. (C, D) D1/DR2-bearing c-Fos-ir MSNs (white arrowheads), DR2-
bearing c-Fos immunonegative MSNs (blue arrowheads), and non-DR1/
DR2-bearing c-Fos or MSNs (yellow arrows). Scale bar = 50 μm. (E) PPN
cholinergic stimulation exerted an overall potentiating effect on ipsilateral
striatal DR1-MSNs in lesioned (n = 6) compared with sham control rats
(*p = 0.0182, n = 6). (F) In contrast, ipsilateral DR2-MSNs’ neural activity
in lesioned rats compared with shams reduced significantly during CNO
ON (***p < 0.0001) (n = 6). (G) A low-power photomicrograph (tiled
image, left) reveals c-Fos immunofluorescence, at approximately coronal
position − 2.3 mm (relative to bregma) of a rat brain stereotaxic atlas [28],
with enlarged view shown on the right. Scale bar = 1 mm. (H) Compared
with CNO OFF (n = 6), PPN cholinergic neuronal stimulation did not alter
c-Fos expression levels within Vm and Vl thalami neurons, but substantial-
ly increased the expression in the Vl versusVm (**p = 0.009, n = 6). Error
bars depict SEM throughout
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PPN Cholinergic Activation Results in Contrary Effects
on DR1- Versus DR2-Bearing MSNs
c-Fos expression was quantified stereologically and expressed
as a proportion of the total number of DR1-bearing MSNs of
each striatum. MSNs were labeled by DARPP-32 immuno-
staining (Fig. 4C, D), a “dual-function” DA- and cAMP-
regulated phosphoprotein whose phosphorylation at separate
threonine residues (34 and 75) has been shown to separately
inhibit protein phosphatase-1 and protein kinase A in DAergic
neurons [53–55]. DARPP-32 is expressed in both DR1- and
DR2-bearingMSNs (in rodents and primates), but not in other
GABAergic (inter)neurons of the striatum; hence, it is consid-
ered a cellular marker for MSNs [56, 57]. The level of MSNs
ipsilateral to the lesioned nigra (with secondary PPN lesion)
that co-expressed DR1 or DR2 c-Fos, where animals had been
culled either at the CNO OFF or CNO ON stage, was com-
pared with the values for the nonlesioned contralateral side.
The mean difference for the percentage DR1-c-Fos MSNs
between contralateral and ipsilateral striata in animals during
an unstimulated state was deemed negligible, at 14.6 ± 1.1%
(p > 0.05, n.s., n = 6) (Fig. 4E). In stimulated animals, the
pattern was entirely reversed with higher c-Fos expression
seen on the ipsilateral side (91.2 ± 2%) compared with either
the intact contralateral side in the same animals (77 ± 4%)
(*p = 0.0182) or when evaluated against the ipsilateral side
of rats in a CNO OFF state (70.7 ± 0.9%) (****p < 0.0001,
n = 6) (Fig. 4E).
The same evaluation performed on DR2-bearing MSNs
showed a contrary effect (Fig. 4F); the mean difference in
the level of MSNs co-expressing DR2 and c-Fos on the ipsi-
lateral side in unstimulated rodents was 90.1 ± 4.1%, com-
pared with when rats were stimulated (53.4 ± 3.1%) (****p
< 0.0001). Taken together, our results reveal that activity with-
in the classically described DR1-mediated “direct” pathway is
increased ipsilaterally upon PPN stimulation but reduced on
the similar hemispheric side in the DR2-mediated “indirect”
pathway. These data provide evidence for a DREADD-
dependent reversal of baseline activity imbalance at the striatal
level, which in itself appears dependent on nigral DA loss,
reflecting classical PD-induced changes in basal ganglia
circuitry.
PPN Cholinergic Stimulation Increases Differential
Neuronal Activity Between Thalamic Substructures
but Did Not Generate Substantial Overall Thalamic
Activation
The neuronal nuclear antigen NeuNwas used to immunolabel
neurons of the thalamus, which was subsequently separated
into the Vl and Vm thalamic subregions, by referring to a
stereotaxic atlas [28], its boundaries that were digitally
superimposed on matching sections (Fig. 4G). Vl and Vm
thalamic subregions were assessed as the PPN sends signifi-
cant cholinergic efferent projections to these brain regions,
with these PPN output regions that associate with regulating
several aspects of motor behavior [23, 24]. In lesioned ani-
mals, no significant change was noted for mean ipsilateral–
contralateral Vl neuronal c-Fos levels, during CNO stimula-
tion (8.2 ± 2%, n = 6) compared with the CNOOFF stage (5.3
± 4.1%) (p = 0.55, n.s., n = 6) (Fig. 4G, H). A similar nonsig-
nificant effect was seen for Vm c-Fos expression (CNO ON
1.1 ± 1.9%; CNO OFF 0.5 ± 4%) (p = 0.90, n.s.). However,
during CNO ON, implying PPN cholinergic activation, Vl
thalamic neurons were significantly more activated than Vm
ones (**p = 0.009) (Fig. 4H).
Discussion
DREADD are mutated G protein-coupled receptors that are
overexpressed within specific neurons, brain regions, or pro-
jection pathways. This allows for overexpressed receptors in-
tegrated into the neuronal membrane of targeted elements to
be silenced or activated in response to the systemic injection
of a synthetic agonist for the DREADD, to ultimately permit
for dissecting out the neuronal substrate underlying specific
behavior. The current study is the first to demonstrate that the
combination of 2 powerful techniques, DREADD and in vivo
PET imaging, can be used with a significant effect to dissect
out the functional role of PPN-originating cholinergic path-
ways, for explaining some of the clinical benefits associated
with PPN-DBS to alleviate PD-related disability. By utilizing
cholinergic-selective stimulation of remaining PPN neurons in
a well-validated rat model of PD, which mirrors both the
DAergic nigrostriatal and cholinergic PPN neurodegeneration
seen in human PD [10–13], we uniquely demonstrated that the
reversal of motor deficits is principally due to PPN cholinergic
neurons’ innervation of the nigrostriatal pathway.
We utilized a comprehensive behavioral repertoire to vali-
date the lesion in toxin-lesioned animals, but also to determine
the potential of this region-restricted cell-type-specific stimu-
lation paradigm to alleviate PD-related motor deficits. Taken
together, the results of the behavioral tests confirm that
lactacystin-lesioned rats had sustained significant neuronal
loss, to a level sufficient to severely alter motor performance
in a variety of tasks. Further supporting this, subsequent post-
mortem stereological evaluations of nigral TH-ir and PPN
ChAT-ir neurons found significant loss of such neuronal
groups on the toxin-lesioned brain hemispheric side, com-
pared with the nonlesioned side and also sham-lesioned ani-
mals. Future work should concern deeper phenotypic charac-
terization of the motor and neuronal substrate impairments
reported here and in our previous work [9–13] for the
lactacystin lesion model of PD. In particular, correlations
drawn between the different motor function parameters and
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the number of TH-ir as well as ChaT-ir neuronal cell loss will
be insightful for the ongoing characterization of this animal
model, with such knowledge that will ultimately provide a
crucial contribution for understanding disease mechanisms
and guiding subsequent novel therapeutic intervention strate-
gies. In such analyses, future work should not only consider
the current combination of measurements, but should also
incorporate alternative outcome measures especially those
measuring gait disturbance. For such detailed profiling, the
behavioral readouts should be correlated with the magnitude
of the lesions at several levels. In relation to the dopaminergic
lesion, associations should be ascertained between the extent
of behavioral impairments and the reduction in dopamine con-
tent in the lesioned striatum, the level of lost TH-ir innervation
in the ipsilateral striatum, and nigral TH-ir neuronal counts.
Similar analyses should determine for the association between
the PPN ChAT-ir neuronal counts and various motor outputs;
however, as our current results show, deficiency in these and
also their rescue are likely to result from the complex interplay
between the cholinergic and dopaminergic systems.
SNpc DAergic neurons represent an important output target
of the PPN’s cholinergic projecting neurons [58]. When con-
sidered during CNO OFF, the c-Fos-based activity analysis
showed that loss of DAergic input (secondary to cholinergic
excitation) to DR1s within striatal MSNs of lactacysin-
induced parkinsonian rats results in ipsilateral striatal DR1
overactivation, with a converse effect that was exerted on
DR2s, instead showing downregulated DR2 activity. We pro-
pose that this effect forms the mechanistic basis for the pro-
found motor defects shown by unilateral lactacystin-lesioned
rats and reflects data from other PET imaging studies that also
made use of a D2/3 receptor probe, to reveal that DR1 striatal
levels are typically elevated in PD patients prior to DA substi-
tution therapy [59, 60], similar to that seen in other animal
models of PD [61]. This phenomenon may be considered a
form of denervation supersensitivity that manifests to compen-
sate for diminished DA transmission resulting from the
DAergic lesion [62]. On the other hand, in the same rats, the
PET-based [11C]PHNO displacement analysis during CNOON
evidenced increased striatal DA release, suggesting that the
motor recovery shown by the lesioned rats during cholinergic-
specific PPN stimulation reflects restored DA imbalance at the
striatal level. Immunofluorescence and imaging analysis pro-
vided further mechanistic insight into this effect, by revealing
that the DA release in the striatum exerted reciprocal effects on
the MSNs of the “direct” pathway that predominantly express
DR1s, which contrasted to that seen in the “indirect” pathway
that mainly express DR2s. Hence, PPN-driven cholinergic
overactivation suppressed the activity of striatal DR2-bearing
MSNs, but potentiated DR1 MSN activity. Contralateral c-Fos
expression was comparable during CNO OFF compared with
CNOON, with the neuronal activity change occurring predom-
inantly ipsilaterally, to strongly suggest that chemogenetic
stimulation of the PPN’s cholinergic neurons exerts a powerful
downstream effect on striatal MSN activity.
The data underscores the tight regulation that the PPN’s
cholinergic systems exert over DA transmission at the level
of cell bodies based in the midbrain. In addition to its connec-
tions with the basal ganglia, the PPN also sends dense neuro-
nal projections to the thalamus, a high proportion of these
being cholinergic [63]. Compared with the results we obtained
for nigral and striatal neuronal activation, our study shows that
PPN cholinergic input at the levels of the Vm and Vl thalami
might only play a minimal role in mediating the motor behav-
ioral improvements seen in this rat model of PD, upon selec-
tive activation of PPN cholinergic neurons. No significant
change was detected between CNO ON compared with the
CNO OFF stage when mean ipsilateral–contralateral neuronal
c-Fos levels of either the Vl or ML were compared in lesioned
rats; however, a significant upregulatory effect was seen for
the Vl when compared with the Vm during CNO ON. These
findings warrant further investigation in future work, with
much relating to the structural–functional interactions be-
tween the thalamus, basal ganglia, and PPN that remain to
be ascertained. For instance, output pathways of the Vm tha-
lamic nucleus was suggested to rapidly compensate for func-
tional impairments affecting the Vm [64]. Hence, it remains
possible that the relatively low levels of neuronal activity seen
in the Vm of parkinsonian rats, and also the lack of significant
neuronal activity in the Vm following PPN cholinergic acti-
vation, could be due to such compensatory changes.
The thalamus receives both direct input from the PPN [23,
24], as well as indirect input from the PPN via the striatum,
and could therefore rather be seen as lying further downstream
of the striatum, showing neuronal activity in consequence to
striatal modulation [65]. This view complicates the interpreta-
tion of the present results. Furthermore, at a single-neuronal
level, understanding still lacks as to how information con-
veyed via neurons from the PPN to the thalamus is integrated
into motor control areas. Such complex reciprocal intercon-
nections between the thalamus and PPN, but also between
thalamic neurons and another of the PPN cholinergic neurons’
target, the striatum, suggest for complex patterns of activity
within the thalamus as a result of various inputs, with defini-
tive assertations as to the complex interplay of thalamic-
related feedback pathways involved in the behavioral effects
seen here that lie outside the scope of the current study. Future
work should utilize tools that complement the Fos-based ap-
proach we used here, such as retrograde tracing techniques
using viral vectors for reconstructing axonal arborization and
in vivo electrophysiology recordings by which to map and
subsequently assess thalamic regional differences in neuronal
activation levels, in the presence and absence of PPN
cholinergic-specific excitation.
Taken together, our results showing heightened activation
in both the striatum and SNpc following PPN cholinergic-
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specif ic act ivat ion reinforce the not ion that the
pedunculopontine–nigrostriatal pathway is the most likely
neural pathways underlying the behavioral recovery seen in
this rat model of PD. However, the source of the DA release is
presently unknown, where the current study did not directly
allow for a distinction to be drawn between the degree to
which the striatum versus the SNpcmight provide a functional
connection with the PPN that is sufficient to evoke the behav-
ioral recovery seen in this animal model of PD. Future work
should fully dissect out the relative functional contributions
made by the various neural structures encompassing the
nigrostriatal dopaminergic pathway, toward the improved mo-
tor function reported here. Identifying the involvement of a
neuronal pathway in specific behavior is challenging due to
the large number of synaptic connections in the brain. Here we
described experiments involving DREADD-based stimula-
tion of neuronal cell bodies, and hence, the present study did
not directly address the effects at the axonal ends. The current
data contributes to guiding future work aimed at comparing
output measures resulting from application of pathway-based
neuromodulatory tools to PPN neurons projecting to either the
SNpc of the striatum, with a large body of literature that sup-
ports the presence of such distinct PPN output pathways [6,
21, 22, 25]. Experimental efforts to interrogate the various
components of this functional network could lead to clinically
exploitable substructural targets for improving PPN-DBS de-
livery in a clinical context.
Commonly used treatments for PD are only partially or
transiently effective. Our current findings support the notion
that the most effective therapies for PD should target both the
DA and ACh modulatory systems. Based on our current find-
ings, we propose a model whereby increasing cholinergic con-
trol of DA transmission to modify DR1 and DR2 signaling in
the striatum could alleviate PD-related motor dysfunction.
Future work should determine whether modifying the signal-
ing levels of DR1 and DR2s in this manner could also protect
nigrostriatal DA neurons from toxic damage. Stimulating DA
release from residual DA terminals by means of nicotinic ace-
tylcholine receptor agonists has already been highlighted as a
potentially effective treatment for PD [66]. Our study suggests
the enhancement of hM3 receptor activity as a candidate drug
strategy for disorders involving the DA system including PD,
for potentiating striatal DAergic signaling. In this regard, a
region-specific increase in muscarinic acetylcholine receptors
(mAChRs) seen in PD postmortem brains has been described
as a compensatory mechanism that decelerated the develop-
ment of cognitive symptoms [67]. To validate the therapeutic
viability of this approach, our results will require further elab-
oration with the use of subtype-specific mAChR antagonists.
In support, earlier work has highlighted the therapeutic poten-
tial of muscarinic antagonists against PD [68]. However, the
relative expression of different mAChRs and how such den-
sity changes could underlie PD symptoms remains
underexplored, with such knowledge that could form the basis
for developing more selective ligands for the muscarinic re-
ceptors, hence allowing more targeted approaches for treating
PD. Possibilities include the use of selective allosteric activa-
tors at specific mAChRs for redressing the imbalance in
striatal DA levels in PD-affected brains. This strategy has
shown effectiveness, by avoiding detrimental effects on cog-
nition seen with the use of nonselective mAChRs antagonists
[68].
Clinical evidence in support of an ACh–DA interaction in
the brain includes the finding that degeneration of SNc
DAergic and cholinergic neurons in the nucleus basalis of
Meynert [69] and PPN [15] concurrently commences during
Braak stage III. The role of PPN cholinergic neurons in ana-
tomical studies, which has more recently translated into a fo-
cus placed on their functions, remains an active and evolving
topic in neuroscience. However, balancing the intricate inter-
action at play between these neuromodulatory systems
through the use of pharmacological tools has proved trouble-
some in a clinical context; for instance, use of the DA replace-
ment agent L-DOPA or DAergic agonist drugs was shown to
increase the risk for patients developing cognitive symptoms,
regarded as stemming from cholinergic neuronal loss or dys-
function, following prolonged drug use [70, 71]. In this re-
gard, our study highlights the need for neuromodulatory ther-
apies to consider the intricate interaction between the ACh and
DA neuromodulatory systems, as pharmacological ameliora-
tion of specific aspects of PD, modulated by either the DA/
ACh system, was shown to bring undesirable side effects
through counterproductive effects on the other system [72].
Such contrasting effects by DA- versus ACh-mediated thera-
pies make it crucial that a better understanding be reached as
to DA/ACh interaction at the molecular and circuit levels, for
designing novel and more specific treatments capable of
avoiding such undesirable side effects.
Hence, the current study correlated structural connectivity
between PPN cholinergic neurons and nigrostriatal DAergic
ones to ACh–DA functional connectivity, the activation of
which was sufficient to eliminate motor dysfunction in the
lactacystin-induced rat model of PD. Our findings provide a
contextual framework for such interactions by demonstrating
how the upregulating activity of the PPN cholinergic system
directly modulates the nigrostriatal DA one, to form the mech-
anistic basis of the remarkable recovery in motor function
shown by the parkinsonian rats after receiving PPN choliner-
gic stimulation.
Conclusions and Future Outlook
Our analysis of the activity levels of neurons comprising the
“direct” pathway as well as those of the “indirect” pathway
[73] raises several intriguing possibilities for how cholinergic-
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specific targeting of PPN somas could achieve more effective
alleviation of the axial-related motor dysfunctions seen in PD,
than through the use of conventional DBS that does not offer
cell-type-specific modulation, but rather produces global stim-
ulation of the brain nucleus without discerning between dif-
ferent cell types, thus potentiating undesirable off-target ef-
fects. Because DBS nonselectively modulates local neuronal
activity, it is difficult to tell which of its various network ef-
fects induce therapeutic outcomes and which might cause side
effects. Studies such as ours that investigate the functional
basis of DBS provide information to allow for designing more
effective anti-parkinsonian treatments. In particular, the cur-
rent data could allow for designing medical approaches capa-
ble of improving the ratio between desirable and undesirable
outcomes and leaving nonimpaired functions intact. For ex-
ample, specific genetically defined neurons within precise
subcircuits could be targeted to treat motor symptoms of PD,
without inducing a cognitive detriment, and vice versa. In this
regard, the feasibility for innovative site-specific DBS ap-
proaches combined with pharmacological tools has already
been demonstrated [73].
Current DREADD-based neuromodulatory tools are suit-
able for human CNS disease applications. However, improved
AAV-mediated gene delivery methods [74] as well as devel-
opment of novel, highly selective DREADD agonists [75]
offer clear promise for the extension of DREADD-based
neurotherapeutics to human patients. The promise such novel
clinical strategies hold can only be met if guided by studies
such as the current report, aimed at identifying disease-
relevant neuro-types and subcircuits for therapeutic targeting.
Given the pressing need for developing new, rational therapies
for PD, the development of circuit and cell-type-specific phar-
macological compounds should be considered in designing
optimally targeted therapies.
Limitations
As with the majority of experimental work, some limitations
should be noted for the current study, to be addressed in future
research. Firstly, a translational investigative approach, name-
ly PET imaging, was used to measure in vivo changes in
DAergic signal. Future preclinical studies using more direct
measures of neurotransmitter release with improved temporal
resolution, such as microdialysis or fast cyclic voltammetry,
will allow for discriminating the signal further. Moreover,
some restrictions relating to the presently used c-Fos, as a
reporter of neuronal activation, have been reported, including
low temporal resolution [76–78]. However, c-Fos mRNA or
its protein product remains 1 of the most reliable cellular
markers by which to identify neuronal activation in the brain
[40, 78–80], with Fos-based approaches utilizing immunohis-
tochemical reporters that are particularly suited for application
to neurons of interest residing within deep brain nuclei, such
as the neuronal structures that were studied here. To expand on
the present findings, future studies should include alternative
technologies relative to a c-Fos reporter assay, i.e., by corre-
lating the increased c-Fos activity in the striatum and SNpc
following DREADD-based PPN cholinergic activation with
electrophysiological activity recordings made in these brain
structures.
Lastly, recent rodent-based studies showed that CNO is not
completely inert, but reverse-metabolizes to clozapine, which
can cross the blood–brain barrier to cause its own CNS effects
[81, 82]. However, this view has been challenged by other
works, including reporting no significant retroreduction of
CNO to clozapine in mice [30], whereas Jann and others
[83] reported no detectable clozapine after CNO administra-
tion to rats. In addition, formation of clozapine from CNOwas
shown to be inhibited to ascorbate [84] that is synthesized
endogeneously in rodents [85], suggesting that only limited
CNO retroconversion might be occurring in experimental ro-
dents. Here and also previously [12], we show that the cellular
and behavioral effects induced via PPN-restricted, cholinergic-
specific DREADD excitation are not due to clozapine binding.
Using the same animal model as used here, we transfected
PPN cholinergic neurons with a fluorescently tagged “control”
viral vector, void of the DREADD construct. Cellular and
behavioral effects were compared with those induced by the
activating DREADD-containing viral vector. Because cells
expressing this control construct (hChR2(H134R)-eYFP) are
activated optogenetically [86], but remain unresponsive to
CNO, the strategy allowed for validating that the observed
effects resulted from the DREADD ligand only. Moreover,
we restricted toxin/sham (intra-SNpc) and active DREADD
(intra-PPN) to 1 cerebral hemisphere only, with the
noninjected brain hemisphere serving as internal control,
allowing for ipsilateral–contralateral comparisons across the
midline, e.g., for MSN DR1 and DR2 activation status,
[11C]PHNO BPND and rats’ behavioral performance in tests
relying on cross-midline forepaw placing [35]. In light of re-
cent debate relating to the potential non-DREADD-mediated
effects of CNO, future studies aiming to expand on the current
results should include adequate control conditions to demon-
strate that the observed effects are not due to binding of CNO’s
parent compound, clozapine. It is also worth considering the
reports that direct intracranial CNO administration within a
target region may avoid retroconversion of CNO to clozapine
[87], whereas CNO delivered intracerebroventricularly might
yield more consistent results compared with systemic CNO
administration [88].
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